Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 11/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13147484 | 0.89 | MC4R (0.56) | MC4RLMNAPOLB | |
| SCHEMBL14223731 | 0.88 | MC4R (0.55) | MC4RLMNAPOLB | |
| SCHEMBL13147480 | 0.88 | MC4R (0.53) | MC4RLMNAPOLB | |
| SCHEMBL13147476 | 0.88 | MC4R (0.62) | MC4RLMNAPOLB | |
| SCHEMBL13147449 | 0.85 | MC4R (0.72) | MC4RLMNAPOLB | |
| SCHEMBL13147437 | 0.85 | MC4R (0.72) | MC4RLMNAPOLB | |
| SCHEMBL13147470 | 0.85 | MC4R (0.64) | MC4RLMNA | |
| SCHEMBL13147461 | 0.84 | MC4R (0.56) | MC4RLMNAPOLB | |
| SCHEMBL13147440 | 0.81 | MC4R (0.59) | MC4RLMNAPOLB | |
| SCHEMBL3093411 | 0.80 | MC4R (0.72) | MC4RLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790719-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790719-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7365070-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365070-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20070293498-A1 | Modulators of melanocortin receptor | GENE LOGIC, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293498-A1 | Modulators of melanocortin receptor | GENE LOGIC, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293498-A1 | Modulators of melanocortin receptor | MC4R, MC1R, MC5R | MC4R 1/4885LMNA 4128/4885POLB 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.